Spero Therapeutics (STU:2HA) Cyclically Adjusted Book per Share: €2.56 (As of Mar. 2026)


STU:2HA Spero Therapeutics Inc STU:2HA
44 GF Score
Price €1.88
GF Value €0.90
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spero Therapeutics Cyclically Adjusted Book per Share?

Spero Therapeutics STU:2HA -1.42% 44 Cyclically Adjusted Book per Share is €2.56 as of Mar. 2026. GuruFocus rates STU:2HA with a GF Score™ of 44/100 and a GF Value™ of €0.90 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Spero Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €0.791. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.56 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-04), Spero Therapeutics's current stock price is €1.876. Spero Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €2.56. Spero Therapeutics's Cyclically Adjusted PB Ratio of today is 0.73.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Spero Therapeutics was 0.95. The lowest was 0.73. And the median was 0.90.


Spero Therapeutics  (STU:2HA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Spero Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.876/2.56
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Spero Therapeutics was 0.95. The lowest was 0.73. And the median was 0.90.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Spero Therapeutics Cyclically Adjusted Book per Share Related Terms


Spero Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics Cyclically Adjusted Book per Share Chart

Spero Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spero Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.56

STU:2HA vs VXRT, ADCT, GNLX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Spero Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:2HA
44GF Score
Spero Therapeutics Inc STU:2HA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spero Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Spero Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.791/330.2130*330.2130
=0.791

Current CPI (Mar. 2026) = 330.2130.

Spero Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201512 -1.240 236.525 -1.731
201609 0.000 241.428 0.000
201612 -2.655 241.432 -3.631
201703 0.000 243.801 0.000
201706 2.111 244.955 2.846
201709 -5.147 246.819 -6.886
201712 4.975 246.524 6.664
201803 4.207 249.554 5.567
201806 3.888 251.989 5.095
201809 5.901 252.439 7.719
201812 5.900 251.233 7.755
201903 5.768 254.202 7.493
201906 5.187 256.143 6.687
201909 4.509 256.759 5.799
201912 3.497 256.974 4.494
202003 3.670 258.115 4.695
202006 3.115 257.797 3.990
202009 4.341 260.280 5.507
202012 3.709 260.474 4.702
202103 3.365 264.877 4.195
202106 2.522 271.696 3.065
202109 2.952 274.310 3.554
202112 2.412 278.802 2.857
202203 1.732 287.504 1.989
202206 0.969 296.311 1.080
202209 0.766 296.808 0.852
202212 1.367 296.797 1.521
202303 1.152 301.836 1.260
202306 0.962 305.109 1.041
202309 0.949 307.789 1.018
202312 1.849 306.746 1.990
202403 1.644 312.332 1.738
202406 1.385 314.175 1.456
202409 1.087 315.301 1.138
202412 0.807 315.605 0.844
202503 0.560 319.799 0.578
202506 0.507 322.561 0.519
202509 0.401 324.800 0.408
202512 0.893 324.054 0.910
202603 0.791 330.213 0.791

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €2.56 mean?
Spero Therapeutics (STU:2HA) has a Cyclically Adjusted Book per Share of €2.56 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Spero Therapeutics and its competitors.
Is Spero Therapeutics' Cyclically Adjusted Book per Share too high?
Spero Therapeutics' current Cyclically Adjusted Book per Share is €2.56. Overall, Spero Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Cyclically Adjusted Book per Share compare to VXRT and ADCT?
Spero Therapeutics' Cyclically Adjusted Book per Share of €2.56 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Spero Therapeutics and its competitors. Spero Therapeutics's current Cyclically Adjusted Book per Share is €2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (STU:2HA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.90, compared to a current price of €1.88 — trading 108.4% above its estimated fair value. The current Cyclically Adjusted Book per Share is €2.56. Spero Therapeutics' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Spero Therapeutics (STU:2HA), the current Cyclically Adjusted Book per Share is €2.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (STU:2HA) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of €1.88 is trading 108.4% above its estimated GF Value™ of €0.90. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:2HA:

  • Cyclically Adjusted Book per Share: €2.56
  • GF Value™: €0.90 vs. price of €1.88 (108.4% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the STU:2HA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spero Therapeutics Business Description

Other Exchanges SPRO:USA
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
44GF Score

Get the complete analysis for STU:2HA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.88
Price
€0.90
GF Value